Objectives: To assess HIV-1 post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavirboosted lopinavir versus cobicistat-boosted elvitegravir as a single-tablet regimen (STR), using tenofovir disoproxil fumarate/emtricitabine with both of these therapies.
Introduction
Post-exposure prophylaxis (PEP) toxicity is the main reason for poor adherence and high rates of discontinuation of treatment. 1 Newly controlled clinical trials comparing lopinavir/ritonavir versus the integrase inhibitor raltegravir, using tenofovir disoproxil fumarate/emtricitabine as backbone for both treatments, observed a significant improvement in tolerance and adherence with raltegravir. 2 Elvitegravir, an integrase inhibitor, with tenofovir disoproxil fumarate/emtricitabine as backbone may be a good choice for PEP. [3] [4] [5] A recent pharmacokinetics study in nonhuman primates showed high and sustained concentrations of elvitegravir in rectal and vaginal mucosa. 6 In addition, elvitegravir can be administered as one pill a day, and a low incidence of side effects and dropouts have been reported. 5 There are no studies comparing single-tablet regimens (STRs) with multiple-tablet regimens (MTRs) . Our group has performed a clinical trial comparing cobicistat-boosted elvitegravir versus ritonavir-boosted lopinavir, using tenofovir disoproxil fumarate/ emtricitabine as backbone in both cases, to assess PEP completion rates, adherence and adverse effects. 
Methods
We performed an open, randomized clinical trial. Participants were individuals who attended the emergency room (ER) of our hospital between June 2015 and December 2015, due to potential exposure to HIV. PEP recommendations were performed according to Spanish guidelines. 7 Individuals who were 18 years old, agreed to participate and signed an informed consent were randomized 3:1 to receive either tenofovir disoproxil fumarate/emtricitabine plus elvitegravir/cobicistat once daily (n " 119) or tenofovir disoproxil fumarate/emtricitabine plus lopinavir/ritonavir twice daily (n " 38). Figure 1 shows the study flow chart. A full 28 day prescription was given and initiated immediately (day 0). A computer-generated list of numbers was used to randomize the participants. Prophylactic measures for other sexually transmitted infections (STIs) were administered following current recommendations. 7 HIV testing in the ER was not performed due to our hospital protocols and therefore HIV-negative status could not be confirmed before starting PEP. The follow-up procedure was explained to patients, and patients were provided with counselling on ART. After randomization, five follow-up visits were scheduled for days 1, 10, 28, 90 and 180. Treatment adherence was reinforced in the follow-up visits of the first month. Adherence was measured at the 28 day visit using the Simplified Medication Adherence Questionnaire (SMAQ). 8 The degree of adherence was calculated based on each patient's responses and we classified below 94% as low adherence, a cut-off that has been previously implemented by other authors. 8, 9 Adverse events were assessed and graded at every scheduled visit, following WHO recommendations. 10 Figure S1 (available as Supplementary data at JAC Online) shows the study design. The primary endpoint was PEP non-completion at day 28. PEP non-completion was considered when the patient was lost to follow-up before day 28, or the treatment was discontinued or switched for any reason, including death. Secondary endpoints were lost to follow-up in subsequent visits, adherence to PEP, number of adverse events and rate of seroconversions.
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Ethics
This study was approved by the hospital research committee (approval number HCB/2014/0346) and by the competent Spanish authorities.
Statistical analysis
The sample size was calculated with a 1 -b statistical power of 80% and a protection level versus the bilateral Type I error of 5%, assuming treatment discontinuation of 25% in the lopinavir/ritonavir arm and 7% in the elvitegravir/cobicistat arm. Since we had no information about treatment initiation until patients attended the day 1 visit, we hypothesized that reasons for not attending could be independent of the type of medication. Consequently, we also performed modified ITT analysis considering all patients who attended at least the day 1 visit with the aim to better assess the effect of medication on PEP non-completion. Individuals who discontinued PEP because they were found to be HIV positive on day 1 or because the sexual partners subsequently were found to be HIV negative were excluded from this analysis. Continuous variables were compared between groups with Student's t-test or a non-parametric Mann-Whitney U-test. Categorical variables were compared between groups using the v 2 test or Fisher's exact test. A multivariate analysis was used to assess the independent factors associated with PEP non-completion at day 28.
Results

Characteristics of exposed individuals and source partners
The characteristics of the exposed individuals are shown in Table 1 . The median age was 32 years, 95% were males and 92% were MSM. HIV infection was detected in two randomized patients in
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the serology performed on day 1 (one in the elvitegravir/cobicistat arm and one in the lopinavir/ritonavir arm). These patients were referred to an HIV clinic to continue follow-up.
PEP non-completion and lost to follow-up
PEP non-completion at day 28 was 36% (n " 57), with a trend to be higher in the lopinavir/ritonavir arm [lopinavir/ritonavir 47% (n " 18) versus elvitegravir/cobicistat 33% (n " 39), P " 0.10]. Only 123 out of 157 of those who were randomized attended the first scheduled visit, with no significant differences between the two arms (P " 0.73). We performed a modified ITT analysis including only patients who attended at least the day 1 visit (n " 123) and excluding individuals who discontinued PEP because they tested HIV positive on day 1 (n " 2) or because the sexual partner subsequently tested HIV negative (n " 3). The characteristics of this subgroup are shown in Table 1 . PEP non-completion in this subgroup of patients was significantly higher in the lopinavir/ritonavir arm (9 of 27 patients, 33%) than in the elvitegravir/cobicistat arm (14 of 91 patients, 15%, P " 0.04). Of the original cohort, 34% (n " 53) was lost to follow-up at day 28 without significant differences between arms [lopinavir/ritonavir 40% (n " 15) versus elvitegravir/cobicistat 32% (n " 38), P " 0.39]. Only a few patients switched or discontinued due to side effects, or reconsideration of risk (Figure 1) . The proportion of patients with low adherence to PEP was significantly higher among the patients who completed therapy in the lopinavir/ritonavir arm versus the elvitegravir/cobicistat arm (47% versus 9%, P " 0.0001). There was only a single seroconversion in the elvitegravir/cobicistat arm at day 90. This individual reported multiple high-risk exposures before and after starting PEP.
Factors associated with PEP non-completion
The factors associated with PEP non-completion were analysed in a multivariate logistic regression model (Table S1 ). Independent factors associated with higher rates of PEP non-completion were age below the median (P " 0.09), low risk exposure (P " 0.03) and previous PEP (P " 0.05).
Adverse events
Adverse events were only collected in patients who attended at least day 1. Adverse events were reported by 73 (59%) patients and were significantly more common in the lopinavir/ritonavir arm (90% versus 49%, P " 0.0001) (Table S2 ). There was a higher median of adverse events in the lopinavir/ritonavir arm than in the elvitegravir/cobicistat arm [2 (1-4) versus 0 (0-1), P " 0.0001]. There were no potentially life-threating (grade IV) adverse events. Regarding laboratory tests, there were no significant differences between groups. A higher proportion of non-adherent patients presented adverse events when compared with adherent patients (80% versus 52%, P " 0.04).
Discussion
To our knowledge, this is the first randomized clinical trial comparing an STR versus an MTR for PEP. Patients attending an ER due to potential exposure to HIV were randomized to receive lopinavir/ritonavir versus elvitegravir/cobicistat, using tenofovir disoproxil fumarate/emtricitabine as backbone in both cases. Patients allocated to lopinavir/ritonavir showed a higher PEP non-completion rate, poor adherence and adverse events. In addition, we found that poor adherence was associated with adverse events. It should be noted that lopinavir/ritonavir was used twice daily; therefore, we cannot know which variables might influence the outcome (number of tablets, number of doses or the drugs themselves). Factors associated with a significantly higher risk of PEP noncompletion were low risk exposure, age below the median and previous PEP.
The PEP non-completion rate was higher in the lopinavir/ritonavir arm than in the elvitegravir/cobicistat arm. Similar results have Table 1 . Characteristics of exposed individuals from the entire cohort (n " 157) and individuals coming at least to the day 1 visit (n " 123) Post-exposure prophylaxis for HIV infection JAC been found in other studies comparing lopinavir/ritonavir with raltegravir or maraviroc. 2, 11 These results suggest overall a very poor PEP completion for PI regimens and support the use of integrase inhibitors in this setting as the most recent guidelines suggest. 12, 13 In terms of adherence, patients taking lopinavir/ritonavir were less likely to adhere to treatment as compared with patients taking elvitegravir/cobicistat. Similar results were also observed in several meta-analyses comparing STRs versus MTRs in HIV-positive patients, 14, 15 and in a recent prospective single-arm study of elvitegravir/cobicistat for PEP with similar adherence rates for elvitegravir. 16 We also found a higher rate of adverse events in the lopinavir/ritonavir arm compared with the elvitegravir/cobicistat arm, confirming results observed in prospective studies and clinical trials comparing PIs versus integrase inhibitors. 2, 17, 18 Several limitations were encountered in this investigation. First, information was not available from patients who were lost to follow-up at the day 1 visit (21%) or at subsequent visits. Second, most of the study population was MSM (92%) with a small number of women included in this analysis (5%). Third, few data were collected about sexual partner HIV serological condition and other STIs because of their unknown status. Finally, HIV fourthgeneration testing could not be performed to rule out HIV infection on ER consultation due to our hospital protocols.
In conclusion, elvitegravir might be a suitable drug choice for PEP due to its tolerability profile, low rate of adverse events compared with PIs and low rate of poor adherence when compared with MTRs.
